Skip to content

A. oryzae UOX Construct Screen

This page defines a matched construct screen for asking whether A. oryzae can produce active UOX in a topology that survives the intended process and functions at the reaction site. It does not select secretion, predict a yield, establish a serving, or rank koji against another chassis.

Sequence contract

Each build starts from an accession-bound amino-acid sequence and a synthesis record. UniProt Q00511 contains a 302-residue precursor; its annotated chain is residues 2–302, or 301 residues after initiator-methionine removal. GenBank X61766.1 supplies the 906-nt coding record excluding a stop codon. Record whether a construct and its residue numbering include the initiator methionine and stop codon. Do not reuse the conflicting 273-aa/819-bp description from earlier drafts.

Record:

  • parent accession and sequence checksum;
  • wild-type versus engineered mutations;
  • codon-optimization method and final coding sequence;
  • signal peptide, linker, tags, terminator, marker, and integration boundaries;
  • expected localization as a hypothesis, not an observed result.

Matched construct matrix

Use the same parent sequence, promoter class, integration strategy, and assay wherever the topology permits.

Arm Construct question Required measurements
Intracellular/release Is active oligomer produced, retained through processing, and released in the relevant compartment? Total and active UOX by fraction; release kinetics; oligomer state; retained activity after processing and transit.
Direct secretion Does a native A. oryzae signal peptide yield active extracellular UOX without damaging folding or increasing proteolysis? Intracellular and supernatant mass/activity; signal cleavage; glycosylation; oligomer state; extracellular proteolysis.
Surface display Does tethering improve reaction-site access without blocking assembly or activity? Surface localization; active UOX per biomass; substrate access; shedding; peroxide at the reaction site.
Cell-free product Does recovered UOX retain more usable activity than organism-associated formats? Recovery, purity, retained activity, formulation stability, oxygen and peroxide behavior.

amyB, glaA, and constitutive promoters are candidates to compare. amyB and glaA signal peptides are secretion candidates, not defaults. Published behavior with other proteins does not justify a UOX secretion percentage.

Build controls

  • parental A. oryzae processed identically;
  • promoter-only or marker control as appropriate;
  • wild-type UOX alongside any engineered variant;
  • topology-matched inactive or no-UOX control for peroxide and matrix effects;
  • at least two independent verified integrants per build before treating a result as construct-level.

Confirm integration identity and copy number before comparing expression. Measure transcription only as a diagnostic; the decision variable is active UOX in the relevant fraction and final processed material.

Measurement contract

Report:

  • total UOX identity and mass by intracellular, surface, and extracellular fraction;
  • active IU per culture volume, dry biomass, and wet/dry final material;
  • soluble fraction, oligomer state, aggregation, processing cleavage, and glycosylation where relevant;
  • batch variance and strain stability;
  • retained activity after the actual fermentation, harvest, drying/formulation, and simulated-transit sequence;
  • substrate removal, oxygen dependence, peroxide, access, and persistence under validation §1.33.

General fungal secreted-protein titers, promoter strength, copy number, or native-enzyme output cannot be converted into a UOX yield, therapeutic dose, or product claim. Native digestive-enzyme performance is a separate measurement and does not prove that UOX expression maintains or enhances the combined product.

Iteration logic

Observation Next experiment
Transcript present; little UOX protein Check translation, degradation, integration context, and construct identity.
Protein present; low active fraction Check folding, oligomerization, glycosylation, processing, and aggregation.
Active intracellular UOX; poor release/access Compare release and alternative topology arms rather than assuming more expression solves delivery.
Active extracellular UOX; poor processing retention Test formulation/process protection and proteolysis before scaling expression.
Reaction-site activity passes but peroxide fails Test matched scavenger topology/capacity; do not promote the UOX construct alone.
No arm clears §1.33 Stop or redirect the A. oryzae UOX configuration.

Advancement boundary

A topology advances only after it produces reproducible active UOX and clears the physiological substrate, oxygen, peroxide, access, and persistence comparison in §1.33. Validation §1.36 then determines whether animal escalation is justified. Expression yield alone cannot establish dose sufficiency or make a format shippable.

Sources